Related references
Note: Only part of the references are listed.miRNACancerMAP: an integrative web server inferring miRNA regulation network for cancer
Yin Tong et al.
BIOINFORMATICS (2018)
DcR3 induces proliferation, migration, invasion, and EMT in gastric cancer cells via the PI3K/AKT/GSK-3 beta/beta-catenin signaling pathway
Hua Ge et al.
ONCOTARGETS AND THERAPY (2018)
Downregulation of LAPTM5 suppresses cell proliferation and viability inducing cell cycle arrest at G0/G1 phase of bladder cancer cells
Liang Chen et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
Manav Korpal et al.
NATURE COMMUNICATIONS (2017)
Silencing of HJURP induces dysregulation of cell cycle and ROS metabolism in bladder cancer cells via PPARγ-SIRT1 feedback loop
Rui Cao et al.
JOURNAL OF CANCER (2017)
Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer
Jonathan T. Goldstein et al.
CANCER RESEARCH (2017)
Capsaicin Suppresses Cell Proliferation, Induces Cell Cycle Arrest and ROS Production in Bladder Cancer Cells through FOXO3a-Mediated Pathways
Kaiyu Qian et al.
MOLECULES (2016)
Ki-67 acts as a biological surfactant to disperse mitotic chromosomes
Sara Cuylen et al.
NATURE (2016)
Pioglitazone use and risk of bladder cancer: population based cohort study
Marco Tuccori et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Pioglitazone use and risk of bladder cancer: population based cohort study
Marco Tuccori et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Simvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARγ signalling pathway
Gang Wang et al.
SCIENTIFIC REPORTS (2016)
The forces behind EMT and tumor metastasis
Spencer C. Wei et al.
CELL CYCLE (2015)
Association of Cytokeratin and Vimentin Protein in the Genesis of Transitional Cell Carcinoma of Urinary Bladder Patients
Arshad H. Rahmani et al.
DISEASE MARKERS (2015)
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
James D. Lewis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Nuclear Receptors, RXR, and the Big Bang
Ronald M. Evans et al.
CELL (2014)
Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Tahir Chohan et al.
CURRENT MEDICINAL CHEMISTRY (2014)
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
J. Alfred Witjes et al.
EUROPEAN UROLOGY (2014)
Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
Yi-Xiang Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein et al.
NATURE (2014)
Pre-B-cell leukemia homeobox interacting protein 1 is overexpressed in astrocytoma and promotes tumor cell growth and migration
Dannis G. van Vuurden et al.
NEURO-ONCOLOGY (2014)
Cyclin-dependent kinases
Marcos Malumbres
GENOME BIOLOGY (2014)
PPARγ antagonist GW9662 induces functional estrogen receptor in mouse mammary organ culture: potential translational significance
Rajendra G. Mehta et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2013)
Cell death is induced by ciglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) agonist, independently of PPARγ in human glioma cells
Myoung Woo Lee et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Isorhamnetin Inhibits Proliferation and Invasion and Induces Apoptosis through the Modulation of Peroxisome Proliferator-activated Receptor γ Activation Pathway in Gastric Cancer
Lalitha Ramachandran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Pioglitazone and bladder cancer in human studies: Is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
Chin-Hsiao Tseng
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2012)
Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle
Miriam Zanuy et al.
METABOLOMICS (2012)
Diagnosis and Treatment of Bladder Cancer: How Can We Improve?
Michael A. Gorin et al.
POSTGRADUATE MEDICINE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Jeffrey M. Peters et al.
NATURE REVIEWS CANCER (2012)
Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
Carlo Piccinni et al.
DIABETES CARE (2011)
Urothelial carcinoma of the bladder: definition, treatment and future efforts
Sandip M. Prasad et al.
NATURE REVIEWS UROLOGY (2011)
Combined Low Doses of PPARγ and RXR Ligands Trigger an Intrinsic Apoptotic Pathway in Human Breast Cancer Cells
Daniela Bonofiglio et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Growth Factor-Antagonized Rexinoid Apoptosis Involves Permissive PPARγ/RXR Heterodimers to Activate the Intrinsic Death Pathway by NO
Pattabhiraman Shankaranarayanan et al.
CANCER CELL (2009)
Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology
Ahmad Shabsigh et al.
EUROPEAN UROLOGY (2009)
Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer
Peter E. Clark
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Colorectal Cancer Expression of Peroxisome Proliferator-Activated Receptor γ (PPARG, PPARgamma) Is Associated With Good Prognosis
Shuji Ogino et al.
GASTROENTEROLOGY (2009)
Thiazolidinediones and Cardiovascular Risk - A Question of Balance
Erland Erdmann et al.
CURRENT CARDIOLOGY REVIEWS (2009)
Inhibition of Peroxisome Proliferator-Activated Receptor γ Promotes Tumorigenesis Through Activation of the β-Catenin/T Cell Factor (TCF) Pathway in the Mouse Intestine
Toshio Fujisawa et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2008)
Rodent carcinogenicity profile of the antidiabetic dual PPAR α and γ agonist muraglitazar
Sarah H. Tannehill-Gregg et al.
TOXICOLOGICAL SCIENCES (2007)
Peroxisome proliferator-activated receptor-γ antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines
Jack D. Burton et al.
ANTI-CANCER DRUGS (2007)
The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women:: A randomized, controlled trial
Andrew Grey et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials
RJ Sylvester et al.
EUROPEAN UROLOGY (2006)
Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties
Hirokazu Takahashi et al.
CANCER SCIENCE (2006)
Peroxisome proliferator-activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice
K Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells
KL Schaefer et al.
CANCER RESEARCH (2005)
Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists
C Grommes et al.
LANCET ONCOLOGY (2004)
Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662
LM Leesnitzer et al.
BIOCHEMISTRY (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients
JP Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Cell cycle molecular targets in novel anticancer drug discovery
JK Buolamwini
CURRENT PHARMACEUTICAL DESIGN (2000)
Share Paper
